BRSYF Stock Brainsway (BRSYF, $3.4) was the month's biggest loser, descending -41.28%

GET DAILY SIGNALS

Get AI intraday signals

BRSYF - Brainsway Ltd.

Loading...

Price: $3.4

Daily change: -$2.39 (-41.28%)

Daily volume: 900

Monthly price change: -$2.39 (-41.28%)

Capitalization: $160.3M

Industry: Medical Specialties

Brainsway (BRSYF, $3.4) was a top loser this month, diving -4 to $3.4 per share. Of the 402 stocks analyzed in the Medical Specialties Industry throughout this month, of them () exhibited an Uptrend while of them () were in a Downtrend.

BRSYF's Stochastic Oscillator is staying in overbought zone for 1 day

Expect a price pull-back in the near future.

Technical Analysis (Indicators)

Bearish Trend Analysis

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BRSYF just turned positive on November 24, 2025. Looking at past instances where BRSYF's MACD turned positive, the stock continued to rise in of 14 cases over the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BRSYF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.746) is normal, around the industry mean (63.271). P/E Ratio (53.125) is within average values for comparable stocks, (37.178). BRSYF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.671). BRSYF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (7.112) is also within normal values, averaging (35.282).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.